Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Earnings for Nabriva Therapeutics plc (NBRV)
Earnings in 2022 (TTM): $-55,617,000
According to Nabriva Therapeutics plc's latest financial reports the company's current earnings (TTM) are $-55,617,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Nabriva Therapeutics plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-55,617,000 | $-57,185,000 |
| 2021 | $-48,960,000 | $-49,450,000 |
| 2020 | $-69,345,000 | $-69,484,000 |
| 2019 | $-82,663,000 | $-82,764,000 |
| 2018 | $-114,731,000 | $-114,780,000 |
| 2017 | $-73,001,000 | $-74,356,000 |
| 2016 | $-55,562,000 | $-54,890,000 |
| 2015 | $-31,824,940 | $-31,386,526 |
| 2014 | $-16,182,694 | $-16,270,247 |
| 2013 | $16.55 M | $15.48 M |